what is glp 1 meds GLP-1 Drugs from the Gray Market GLP-1 | Summary
Description
Indication 17.6.7
Individual results may vary, and no outcomes are guaranteed
The company said this combination will allow members to achieve better outcomes and even greater weight loss than the pre-program results
[PubMed] [Google Scholar] 2
Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials: efficacy endpoint for alcohol trials
48 In the Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) trial in adult participants with obesity but without T2DM, tirzepatide (10 mg or 15 mg) achieved greater weight loss compared with semaglutide (1.7 mg or 2.4 mg weekly dose): 20.2% (95% CI 21.4 to 19.1) versus -13.7% (95% CI 14.9 to 12.6) at week 72
